Welcome to our dedicated page for Akebia Therapeut SEC filings (Ticker: AKBA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial readouts, FDA letters, and dialysis-channel contracts can turn Akebia Therapeutics� stock overnight—yet the details are buried deep inside dense SEC exhibits. If you have ever searched for Akebia Therapeutics quarterly earnings report 10-Q filing or tried to untangle 300 pages of risk factors, you know the challenge.
Stock Titan solves it. Our platform delivers Akebia Therapeutics SEC filings explained simply with AI-powered summaries that highlight trial milestones, cash-runway disclosures, and licensing revenues the moment each document hits EDGAR. Need real-time alerts for Akebia Therapeutics Form 4 insider transactions? We stream them instantly, so you can monitor Akebia Therapeutics executive stock transactions Form 4 before the market reacts. Want a quick lens on management’s share grants inside the Akebia Therapeutics proxy statement executive compensation? One click shows how incentive packages align with Vafseo’s regulatory path.
From an Akebia Therapeutics annual report 10-K simplified that flags HIF-PH inhibitor trial risks to an Akebia Therapeutics 8-K material events explained report summarizing fast-moving FDA feedback, our coverage is complete. Investors rely on our Akebia Therapeutics earnings report filing analysis to compare quarter-over-quarter Auryxia revenue, and portfolio managers use “understanding Akebia Therapeutics SEC documents with AI� to save hours each reporting season. Whether you’re tracking Akebia Therapeutics insider trading Form 4 transactions or diving deep into clinical milestone disclosures, every filing type�10-K, 10-Q, 8-K, S-3, DEF 14A—is indexed, summarized, and searchable in seconds.
On 1 July 2025, venture fund 5AM Opportunities I, L.P. filed a Form 144 indicating its intent to sell up to 6,422 common shares of Entrada Therapeutics, Inc. (NASDAQ: TRDA) through TD Securities (USA) LLC. The proposed transaction is valued at roughly USD 45,737 and represents only 0.02 % of Entrada’s 37.95 million shares outstanding.
The filing also discloses that the same fund recently sold 19,265 shares on 27 Jun 2025 for USD 133,121 and 6,422 shares on 30 Jun 2025 for USD 43,751, bringing total sales in the past three months to 25,687 shares (� 0.07 % of the float) for gross proceeds of approximately USD 176,872.
The shares were originally acquired on 29 Mar 2021 via a cash-financed venture investment. No operational, earnings, or strategic updates are provided in this notice. Form 144 merely gives advance notice of potential affiliate sales; execution is not assured. Given the small size relative to the public float, the filing is unlikely to materially affect liquidity or valuation but does indicate continued position trimming by an early investor.
Atlassian Corporation (TEAM) � Form 4 Insider Transaction
Co-CEO, Director and 10% owner Michael Cannon-Brookes reported three open-market sales of the company’s Class A common stock on 30 June 2025. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on 20 February 2025.
- Total shares sold: 7,665 (4,653 + 2,748 + 264)
- Weighted-average prices: $203.38, $202.70 and $204.12, respectively
- Aggregate value (approx.): $1.56 million
- Post-sale holdings: the trust (CBC Co Pty Ltd as trustee for the Cannon-Brookes Head Trust) now holds 3,012 TEAM shares; direct ownership lines show no remaining shares for the disclosed accounts.
The filing indicates the sales span a narrow $202�$204 price range, suggesting routine portfolio rebalancing rather than a reaction to unforeseen events. No derivative security activity was reported.
While the absolute dollar amount is modest relative to Cannon-Brookes� multi-billion-dollar stake, any insider sale by a founder-CEO can attract investor attention. The use of a 10b5-1 plan provides an affirmative defense against allegations of trading on non-public information.
FAQ
What is the current stock price of Akebia Therapeut (AKBA)?
What is the market cap of Akebia Therapeut (AKBA)?
What is the core focus of Akebia Therapeutics?
Which products are part of Akebia's portfolio?
How does Vafseo work as a treatment?
What distinguishes Akebia Therapeutics in the biopharmaceutical industry?
How does Akebia support its commercial launch strategies?
What type of clinical research does Akebia undertake?
What role does regulatory approval play in Akebia’s operations?
How does Akebia demonstrate E-E-A-T in its business practices?
